Geode Capital Management LLC Has $708,000 Stock Holdings in Invivyd, Inc. (NASDAQ:IVVD)

Geode Capital Management LLC trimmed its position in Invivyd, Inc. (NASDAQ:IVVD) by 1.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,597,674 shares of the company’s stock after selling 24,547 shares during the period. Geode Capital Management LLC owned about 1.34% of Invivyd worth $708,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Barclays PLC boosted its holdings in Invivyd by 179.6% in the third quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after acquiring an additional 75,780 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Invivyd by 644.1% during the 4th quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company’s stock worth $114,000 after purchasing an additional 222,375 shares during the last quarter. Finally, State Street Corp lifted its position in Invivyd by 3.7% during the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after purchasing an additional 35,904 shares during the period. 70.36% of the stock is owned by institutional investors and hedge funds.

Invivyd Trading Down 3.6 %

Invivyd stock opened at $0.61 on Friday. The firm has a market capitalization of $72.84 million, a P/E ratio of -0.31 and a beta of 0.41. The business has a 50-day moving average of $0.72 and a 200-day moving average of $0.77. Invivyd, Inc. has a 1 year low of $0.35 and a 1 year high of $2.74.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.10. The firm had revenue of $13.80 million for the quarter, compared to analyst estimates of $13.57 million. Research analysts anticipate that Invivyd, Inc. will post -1.64 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on IVVD shares. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Invivyd in a research note on Wednesday, March 26th. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Invivyd in a report on Thursday, March 20th.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.